Morphine Side Effects: Common and Serious Adverse Reactions
Morphine causes predictable adverse effects in the majority of patients, with constipation being the most persistent and requiring prophylactic management, while respiratory depression represents the most serious life-threatening risk requiring close monitoring especially within the first 24-72 hours of initiation or dose escalation.
Most Common Side Effects
Gastrointestinal Effects
- Constipation: Occurs in approximately 88% of patients and is the most persistent side effect, often moderate to severe (62% of cases) 1, 2. Unlike other opioid side effects, constipation does not improve with continued use and requires prophylactic management from treatment initiation 3.
- Dry mouth: Most frequently reported symptom with 95% point prevalence, often moderate to severe (57%), and highly persistent (20% period prevalence) 2.
- Nausea and vomiting: Reported in less than half of patients, typically dose-dependent and improves with time 1, 2. More likely to be severe following dose increases 2.
Central Nervous System Effects
- Sedation/somnolence: Occurs in 88% of patients, often moderate to severe (55%), but typically improves with continued use 1, 2.
- Dizziness and lightheadedness: Common initial side effects that are dose-dependent 1.
- Confusion and cognitive impairment: More common in elderly patients and those with renal impairment 1.
Other Common Effects
- Pruritus (itching): Frequently reported, usually mild 1, 4.
- Myoclonus (muscle twitching): Common (83% point prevalence) but usually mild and not persistent 2.
- Urinary retention: Occurs in 25% of postoperative patients, with higher prevalence in elderly due to benign prostatic hyperplasia or polypharmacy 3.
Life-Threatening Side Effects
Respiratory Depression
This is the most serious adverse effect and the primary cause of opioid-related mortality 1. Key points:
- Risk is greatest during the first 24-72 hours of therapy initiation or following dose increases 1.
- Can occur at any time during treatment, even when used as recommended 1.
- Opioid-induced CO₂ retention exacerbates sedating effects, creating a dangerous cycle 1.
- Accidental ingestion of even one dose by children can be fatal 1.
- Monitor patients continuously during high-risk periods 1.
Sleep-Related Breathing Disorders
- Morphine causes central sleep apnea (CSA) and sleep-related hypoxemia in a dose-dependent fashion 1.
- If CSA develops, reduce opioid dosage using appropriate tapering protocols 1.
Cardiovascular Effects
- Severe hypotension, circulatory depression, shock, and cardiac arrest can occur 1.
- More common with rapid intravenous administration or in volume-depleted patients 1.
Serious Endocrine and Metabolic Effects
Adrenal Insufficiency
- Reported with opioid use, more often following greater than one month of use 1.
- Requires clinical suspicion and appropriate testing 1.
Androgen Deficiency
- Occurs with chronic opioid use, leading to hypogonadism 1.
- Can cause sexual dysfunction, decreased libido, and impotence 1.
Neurological Complications
Seizures
- Morphine can precipitate seizures, particularly at higher doses or in susceptible patients 1.
Neurotoxicity in Renal Impairment
Morphine should be avoided in patients with renal impairment 3, 5. The active metabolite morphine-6-glucuronide and neurotoxic metabolites (morphine-3-glucuronide, normorphine) accumulate in renal failure, causing:
Rotate to fentanyl, hydromorphone, or methadone in patients with renal dysfunction 3, 5.
Special Populations at Higher Risk
Patients Requiring Caution
- Renal impairment: Morphine, codeine, meperidine, and tramadol should be avoided unless no alternatives exist 3, 5.
- Hepatic impairment: More frequent monitoring and dose adjustment required 3.
- Elderly patients: Higher risk of urinary retention, confusion, and falls 3.
- Pregnant women: Prolonged use causes neonatal opioid withdrawal syndrome, which is life-threatening if not recognized 1.
Predictors of Adverse Effects
Based on a large international cohort study of 1,128 emergency department patients, 25% experienced opioid-induced adverse reactions 6. Independent predictors include:
- History of travel sickness (OR 1.7; 95% CI 1.01-2.86) 6
- History of nausea/vomiting post-morphine (OR 3.86; 95% CI 2.29-6.51) 6
Consider prophylactic antiemetic therapy in these high-risk patients 6.
Management Strategies
Initial Approach
- Distinguish morphine side effects from other causes: Rule out comorbidity, dehydration, drug interactions, or disease progression (e.g., spinal cord compression in urinary retention) 3, 7.
- Consider dose reduction: Possibly with addition of co-analgesic agents 7.
If Side Effects Persist
Choose from three evidence-based options 7:
- Symptomatic management of the adverse effect
- Opioid rotation to alternative agent (e.g., fentanyl, hydromorphone, methadone)
- Route switching (e.g., transdermal, subcutaneous)
Specific Management
For constipation:
- Prophylactic laxatives from treatment initiation 3
- Consider methylnaltrexone or low-dose naloxone (0.25 mg/kg/h) infusion 3
For urinary retention:
- Rule out spinal cord compression first 3
- Catheterization in acute cases 3
- Tamsulosin may be beneficial 3
- Rotate to synthetic opioid (e.g., fentanyl) 3
For respiratory depression:
- Close observation and supportive measures 1
- Opioid antagonists (naloxone) depending on clinical status 1
Critical Monitoring Requirements
Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy and following dosage increases 1. This is non-negotiable for patient safety.
For patients with renal or hepatic impairment, perform more frequent clinical observation and opioid dose adjustment 3.
Important Caveat
Serious morphine-related adverse reactions (2% of cases) are rare and largely unpredictable 6. However, the predictable common side effects occur in 73-88% of patients 2, 8, requiring proactive management rather than reactive treatment.